Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy

This article was originally published here

MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enroll 12 patients

The post Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply